Eos Imaging said the FDA approved its hipEos 3D software for planning hip replacement surgery.
Eos said the software uses patients’ anatomical data to create a functional, weight-bearing 3D image that can help physicians determine what size implant to use and how it should be positioned.
Paris-based Eos plans to launch the product in the U.S. at the annual meeting of the American Academy of Orthopedic Surgeons, to be held March 24-28 in Las Vegas. The imaging software received CE Mark clearance in March.
“hipEos is the first step of our strategy to fully utilize Eos’ unique stereo-radiographic 2D/3D patient data in software tools that will help surgeons plan and execute precise surgical and non-surgical treatments,” CEO Marie Meynadier said in prepared remarks. “We are very happy to have been granted market approval in the U.S. and to extend this offering, which has received a very positive feedback at the French SOFCOT launch in November, to our U.S. users and future users.”
Biospace Med rebranded as Eos Imaging back in September 2010. The company has its U.S. headquarters in Cambridge, Mass.